The estimated Net Worth of Alan G Levin is at least $347 Тысяча dollars as of 30 May 2024. Mr. Levin owns over 7,861 units of Biocryst Pharmaceuticals stock worth over $347,471 and over the last 8 years he sold BCRX stock worth over $0. In addition, he makes $0 as Independent Director at Biocryst Pharmaceuticals.
Sign up
Mr. Levin BCRX stock SEC Form 4 insiders trading
Alan has made over 1 trades of the Biocryst Pharmaceuticals stock since 2024, according to the Form 4 filled with the SEC. Most recently he bought 7,861 units of BCRX stock worth $49,996 on 30 May 2024.
The largest trade he's ever made was buying 7,861 units of Biocryst Pharmaceuticals stock on 30 May 2024 worth over $49,996. On average, Alan trades about 314 units every 0 days since 2016. As of 30 May 2024 he still owns at least 44,951 units of Biocryst Pharmaceuticals stock.
You can see the complete history of Mr. Levin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Alan Levin biography
Alan G. Levin CPA serves as Independent Director of the Company. In addition to his 20-year career at Pfizer, Mr. Levin served as CFO of Endo Pharmaceuticals, Inc. over a five-year period where the company experienced a nearly 400 percent increase in its market capitalization. He currently serves on the BOD of Diffusion Pharmaceuticals, Inc., a development stage company focused on therapeutics to enhance the effectiveness of treatments for stroke and cancer, and on the advisory board of Auven Therapeutics, a global private equity fund that acquires and pursues accelerated development of breakthrough therapeutic drugs, prior to licensing them to commercial partners. From 2014 through 2019, Mr. Levin served on the BOD of Aceto Corporation, a multinational company involved in the sale and distribution of generic drugs, pharmaceutical intermediates and performance chemicals. He also serves on the BOD of the Critical Path Institute, a nonprofit collaboration between the U.S. Food and Drug Administration and the pharmaceutical industry, focused on streamlining and accelerating the development and regulatory pathways for innovative medicines. Mr. Levin is an audit committee financial expert, as defined by the Securities and Exchange Commission, and is a certified public accountant. He holds a bachelor’s degree from Princeton University and a master’s degree from New York University’s Stern School of Business.
How old is Alan Levin?
Alan Levin is 57, he's been the Independent Director of Biocryst Pharmaceuticals since 2020. There are 12 older and 10 younger executives at Biocryst Pharmaceuticals. The oldest executive at Biocryst Pharmaceuticals Inc. is Robert Ingram, 77, who is the Independent Chairman of the Board.
What's Alan Levin's mailing address?
Alan's mailing address filed with the SEC is 4505 EMPEROR BLVD., SUITE 200, DURHAM, NC, 27703.
Insiders trading at Biocryst Pharmaceuticals
Over the last 24 years, insiders at Biocryst Pharmaceuticals have traded over $76,362,383 worth of Biocryst Pharmaceuticals stock and bought 4,042,003 units worth $20,848,654 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Brothers Life Sciences Capi... и Carl L Gordon. On average, Biocryst Pharmaceuticals executives and independent directors trade stock every 31 days with the average trade being worth of $542,329. The most recent stock trade was executed by Amy E Mc Kee on 24 June 2024, trading 8,600 units of BCRX stock currently worth $54,352.
What does Biocryst Pharmaceuticals do?
biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.
What does Biocryst Pharmaceuticals's logo look like?
Complete history of Mr. Levin stock trades at Biocryst Pharmaceuticals и Diffusion Pharmaceuticals Inc
Biocryst Pharmaceuticals executives and stock owners
Biocryst Pharmaceuticals executives and other stock owners filed with the SEC include:
-
Jon Stonehouse,
President, Chief Executive Officer, Director -
Megan Sniecinski,
Senior Vice President, Chief Business Officer -
Alane Barnes,
Senior Vice President, Chief Legal Officer and Corporate Secretary -
Jon P. Stonehouse,
CEO, Pres & Exec. Director -
Yarlagadda Babu,
Senior Vice President - Drug Discovery -
William Sheridan,
Senior Vice President, Chief Medical Officer -
Dr. William P. Sheridan,
Chief Medical Officer & Sr. VP -
Dr. Yarlagadda S. Babu,
Chief Discovery Officer -
Stephen Aselage,
Independent Director -
Robert Ingram,
Independent Chairman of the Board -
Kenneth Lee,
Independent Director -
Nancy Hutson,
Independent Director -
George Abercrombie,
Independent Director -
Theresa Heggie,
Independent Director -
Helen Thackray,
Independent Director -
Dr. Helen M. Thackray FAAP, M.D.,
Chief R&D Officer -
Anthony Doyle,
Chief Financial Officer, Senior Vice President -
Alan Levin,
Independent Director -
Charles Gayer,
Senior Vice President, Chief Commercial Officer -
Allen Hodge,
Vice President and General Manager for the United States -
Michael Jones,
Executive Director - Finance, Principal Accounting Officer -
Alane P. Barnes,
Sr. VP, Chief Legal Officer & Corp. Sec. -
Michael L. Jones,
Exec. Director of Fin. & Principal Accounting Officer -
Dr. Elliott T. Berger,
Sr. VP of Regulatory Affairs -
Robert C. Stoner,
VP of HR -
John D. Bluth,
Sr. VP of Investor Relations & Corp. Communications -
Anthony Doyle,
Sr. VP & CFO -
Sanj K Patel,
Director -
Stanley C Erck,
Director -
Fred E Cohen,
Director -
Lynne Powell,
Senior VP - CCO -
Thomas R Ii Staab,
Senior Vice President and CFO -
Bros. Advisors Lp Baker Bro...,
-
John L Higgins,
Director -
Felix Baker Bros. Investmen...,
-
Zola P Horovitz,
Director -
Robert S Lowrey,
Controller, PAO -
Steven K Galson,
Director -
Steve Aselage,
Director -
Brothers Life Sciences Capi...,
-
David Mc Cullough,
VP -
Bros. Capital (Gp), Llcbake...,
-
Stephen R Biggar,
Director -
Stuart Grant,
SR VP & CFO -
Beth C Seidenberg,
Director -
William W Featheringill,
Director -
/ Tisch Capital (Gp), Llcba...,
-
Biotech Capital (Gp), Llcba...,
-
Capital (Gp), Llcbaker Juli...,
-
Mike Mills,
Principal Accounting Officer -
Partners L P/Ilbiotechnolog...,
-
Carl L Gordon,
Director -
Charles E Bugg,
CEO -
J Claude Bennett,
President -
John A Montgomery,
Director -
Jonathan M Nugent,
VP Corp Communications -
W James Alexander,
SR. VP, Chief Medical Officer -
Randall B Riggs,
VP Business Development -
Michael A Darwin,
CFO -
Randolph C Steer,
Director -
Joseph H Jr Sherrill,
Director -
William M Iii Spencer,
Director -
Charles A Sanders,
Director -
Peder Jensen,
Director -
Amy E Mc Kee,
Director -
Machelle Sanders,
Director -
Vincent Milano,
Director